A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00583830. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Mapatumumab in Combination With Carboplatin and Paclitaxel as First Line Therapy in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
Study identification
- NCT ID
- NCT00583830
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2007 (Type not available)
- Primary completion
- Nov 2010 (Actual)
- Completion
- Feb 2011 (Actual)
- Last update posted
- Aug 8, 2013
2007 – 2011
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Birmingham Hematology and Oncology Associates, LLC | Birmingham | Alabama | 35213 | — |
| Desert Hematology Oncology Medical Group, Inc. | Rancho Mirage | California | 92270 | — |
| University of Colorado Health Sciences Center | Aurora | Colorado | 80045 | — |
| Osceola Cancer Center | Kissimmee | Florida | 34741 | — |
| Palm Beach Cancer Institute | West Palm Beach | Florida | 33401 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| LaGrange Oncology Associates | LaGrange | Illinois | 60525 | — |
| Orchard Research, LLC | Skokie | Illinois | 60076 | — |
| Kentuckiana Cancer Institute, PLLC | Louisville | Kentucky | 40202 | — |
| University of Maryland, Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Chevy Chase Health Care | Chevy Chase | Maryland | 20815 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Medical University of South Carolina: Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| The Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| UT Health Science Center at San Antonio, Be Well Center | San Antonio | Texas | 78229 | — |
| Fairfax-Northern Virginia Hematology Oncology, PC | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00583830, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 8, 2013 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00583830 live on ClinicalTrials.gov.